Cross-Sector entity
Of the tracked stories, 4 of 4 also mention 5th U.S. Circuit Court of Appeals, the most common co-covered peer. The clearest coverage concentration is court-decisions: 1 of 4 stories, with the rest divided among 3 other categories. We currently track 4 Cross-Sector stories that mention Liz Murrill, published between September 9, 2026 and September 12, 2026.
4 verified stories tracked
Last mentioned: Sep 12, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 75 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 4 of 4 also mention 5th U.S. Circuit Court of Appeals, the most common co-covered peer. The clearest coverage concentration is court-decisions: 1 of 4 stories, with the rest divided among 3 other categories. We currently track 4 Cross-Sector stories that mention Liz Murrill, published between September 9, 2026 and September 12, 2026. The tracked stories average 2 original sources each.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Liz Murrill. Shared-story counts are live from our verified record — not editorial picks.
5th Circuit hears mifepristone arguments
Louisiana AG Liz Murrill and Rosalie Markezich argue for tighter prescribing rules before a three-judge panel in New Orleans.
Louisiana pill access estimated at 770–900 monthly
A Society for Family Planning survey estimates that 770–900 Louisiana women per month obtained abortion pills from out-of-state providers under shield laws.
Supreme Court allows states to decide abortion issue
The Dobbs decision clears the path for state abortion bans and sets up the current legal battles over cross-border medication abortion.
Medication abortion using mifepristone and misoprostol is now the standard of care for most US abortions. A 5th Circuit ruling could disrupt telehealth prescribing and shield-law access for 770 to 900 Louisiana women each month. The FDA's concurrent safety review adds clinical-policy uncertainty.
Source: nbcsandiego.com · nbcwashington.com
A Fifth Circuit panel is weighing whether federal courts or the FDA should govern mifepristone prescribing, with state shield laws and cross-border pill access at issue. The case is one of three appeals seeking to restrict medication abortion.
Medication abortion accounts for at least 60% of U.S. abortions, and a lawsuit could restrict mifepristone prescribing in states where abortion is legal. Clinicians and telehealth providers face uncertainty over cross-border prescriptions and FDA rules.
For biopharma, the dispute over mifepristone prescribing rules is a test of FDA regulatory authority over an approved drug's risk evaluation and mitigation strategy. The case may influence how drug safety restrictions are litigated and how federal preemption applies to medication abortion.
Source: MedPage Today · chicagotribune.com
